Drug Approval | October 04, 2021
Lilly to transfer rights of two diabetes drugs to Cipla in India
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
According to WHO, over 1.5 million people died of TB in 2020
At present 18 per cent of the local pharmaceutical market is under government's price control
The drug is also intended for the treatment of glioblastoma multiforme
Subscribe To Our Newsletter & Stay Updated
